Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial

@article{Voskuhl2016EstriolCW,
  title={Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial},
  author={R. Voskuhl and H. Wang and T. Wu and N. Sicotte and R. Elashoff},
  journal={The Lancet Neurology},
  year={2016},
  volume={15},
  pages={35-46}
}
  • R. Voskuhl, H. Wang, +2 authors R. Elashoff
  • Published 2016
  • Medicine
  • The Lancet Neurology
    • BACKGROUND Relapses of multiple sclerosis decrease during pregnancy, when the hormone estriol is increased. Estriol treatment is anti-inflammatory and neuroprotective in preclinical studies. In a small single-arm study of people with multiple sclerosis estriol reduced gadolinium-enhancing lesions and was favourably immunomodulatory. We assessed whether estriol treatment reduces multiple sclerosis relapses in women. METHODS We did a randomised, double-blind, placebo-controlled phase 2 trial at… CONTINUE READING
    View on Elsevier
    escholarship.org
    97 Citations
    Highly Influencial Citations
    2
    Background Citations
    18
    Methods Citations
    5
    Results Citations
    3

    Supplemental Clinical Trials

    Interventional Clinical Trial
    A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)
    This is a double-blinded, placebo controlled study of estriol pills versus placebo pills in relapsing remitting multiple sclerosis. The study treatment will be an added on to Copaxone… Expand
    ConditionsRelapsing Remitting Multiple Sclerosis
    InterventionDrug
    University of California, Los Angeles
    March 2007 - July 2014
    Explore Further
    Discover more papers related to the topics discussed in this paper

    Paper Mentions

    Interventional Clinical Trial
    Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
    Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with cognition. Currently, there are no FDA-approved treatments targeting cognitive function in… Expand
    ConditionsPrimary-progressive Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis
    InterventionDrug, Other
    University of California, Los Angeles
    October 2011 - April 2022
    Interventional Clinical Trial
    A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis
    Duavee is a hormone receptor modulator that has been approved for the treatment of menopausal symptoms in menopausal women. The goal of this 8-week randomized, double blind, placebo… Expand
    ConditionsMenopause, Multiple Sclerosis
    InterventionDrug
    University of California, San Francisco
    February 2016 - April 2019
    Blog Post
    A Fix For Gender-Bias In Animal Research Could Help Humans
    Shots - Health News
    10 February 2016
    Blog Post
    A Fix For Gender-Bias In Animal Research Could Help Humans
    Health
    10 February 2016
    News Article
    Taking Studies of Sex Differences to the Next Level
    Multiple Sclerosis Discovery Forum
    6 February 2016
    Blog Post
    Estriol Reduced Multiple Sclerosis Relapses
    Medical Research News and Interviews: MedicalResearch.com
    7 December 2015
    97 Citations
    Citation Type

    Citation Type

    Why use sex hormones in relapsing-remitting multiple sclerosis? – Authors' reply
    • 4
    Oral contraceptives and MS disease activity in a contemporary real-world cohort
    • 8
    Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol.
    • 1
    Impact of natural menopause on multiple sclerosis: a multicentre study
    • 8
    Estriol: emerging clinical benefits
    • 13
    Pregnancy: Effect on Multiple Sclerosis, Treatment Considerations, and Breastfeeding
    • 37
    • PDF
    Hormone replacement in menopausal women with multiple sclerosis
    • 1
    • PDF
    Reproductive Issues in MS
    • 8
    Testosterone and estrogen in multiple sclerosis: from pathophysiology to therapeutics
    • 11
    Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use
    • D. Wynn
    • Medicine
    • Multiple sclerosis international
    • 2019
    • 6
    • PDF

    References

    SHOWING 1-10 OF 54 REFERENCES
    Treatment of multiple sclerosis with the pregnancy hormone estriol
    • 407
    • PDF
    European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis
    • 724
    Immune Modulation in Multiple Sclerosis Patients Treated with the Pregnancy Hormone Estriol 1
    • 243
    • PDF
    Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
    • 2,356
    • PDF
    A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections.
    • 779
    • PDF
    Efficacy and safety of oral estriol for managing postmenopausal symptoms.
    • 42
    • PDF
    No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis
    • 75
    • PDF
    Randomized phase 2 trial of NP001–a novel immune regulator: Safety and early efficacy in ALS
    • 53
    • PDF
    Results of a 5 years prospective study of estriol succinate treatment in patients with climacteric complaints.
    • C. Lauritzen
    • Medicine
    • Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
    • 1987
    • 33
    Multiple sclerosis drugs: how much bang for the buck?
    • 4